RSV-Related Pneumonia in the Elderly Can Be Prevented with Vaccination

Respiratory Syncytial Virus (RSV) is a virus that causes respiratory tract infections and is the second leading cause of viral pneumonia in the elderly. Symptoms are similar to influenza, including fever, cough, runny nose, shortness of breath, and wheezing.Many people believe RSV only affects young children, but in reality, older adults-especially those with underlying conditions such as diabetes, heart disease, or chronic lung disease-are at high risk of developing RSV-related pneumonia, which can be severe and even life-threatening.

 

Transmission of RSV-Related Pneumonia

    Respiratory Syncytial Virus (RSV) spreads easily through respiratory droplets from coughing or sneezing, as well as through contact with infected secretions. One infected person can transmit the virus to up to three others, especially in enclosed or crowded environments such as hospitals, elderly care facilities, or within households.

 

Why Are Older Adults at Higher Risk from RSV-Related Pneumonia?

The immune system naturally declines with age, making older adults more vulnerable to infections and severe complications compared to other age groups. Among elderly patients infected with RSV, serious complications may include:

 - 78% develop pneumonia

 - 17% experience heart failure

 - 7% develop myocardial ischemia (reduced blood flow to the heart)

 - In some cases, the infection can be life-threatening, with a mortality rate as high as 26.7%.

 

Can RSV-Related Pneumonia Be Treated?

Currently, there is no specific antiviral treatment for RSV. Management is mainly supportive, such as providing oxygen therapy and intravenous fluids.Even after recovery, some patients may experience long-term effects, including reduced lung function and decreased ability to perform daily activities.

 

Who Is at High Risk?

 - Adults aged 60 years and older

 - Individuals with underlying conditions such as diabetes, hypertension, heart disease, or chronic lung disease

 

Prevention Option: RSV Vaccine (Adjuvanted Vaccine)

Although there is no specific treatment for RSV-related pneumonia, vaccines have now been developed specifically for older adults. These are adjuvanted vaccines, designed to enhance the immune system’s response to RSV effectively.

Key Features of the RSV Vaccine

  - Developed for individuals aged 60+, or 50+ with underlying conditions (e.g., diabetes, heart disease, chronic lung disease)

  - Contains an adjuvant to boost immune response

  - Provides protection against multiple RSV strains

  - Up to 94.6% effectiveness in reducing the risk of lower respiratory tract infection in high-risk groups

 

When Should You Get the RSV Vaccine?

Vaccination is recommended for:

  - Adults aged 60 years and older, or

  - Adults aged 50 years and above with comorbidities

Ideally, vaccination should be done before the rainy season (July-November) or prior to peak respiratory infection periods, allowing the body to build immunity in advance.

 

RSV-related pneumonia may initially resemble a common cold, but it can rapidly progress to severe illness-especially in older adults with underlying conditions. If you or your loved ones are in a high-risk group, it is advisable to consult a healthcare professional about vaccination for proper protection.

 

 

Source : Thai Nakarin Hospital

Thai Nakarin Hospital

**Translated and compiled by ArokaGO Content Team